North America Multiomics Market Size, Share & Trends Analysis Report By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics), By Country (U.S., Canada) and Forecast, 2026-2034

Multiomics Market Trends

AI-Enabled Integration and Higher-Throughput Molecular Profiling

Integrated analysis is moving from disconnected bioinformatics pipelines toward cloud-based and AI-assisted environments capable of processing 2, 3 or more molecular modalities simultaneously. In January 2026, Illumina commercially released Connected Multiomics after input from 40 early-access users, integrating genomics, transcriptomics, proteomics and epigenomics workflows. In February 2026, version 1.1 added AI-assisted analytical suggestions, demonstrating the shift toward lower-complexity interpretation of high-dimensional datasets.

Spatial and single-cell workflows are simultaneously increasing experimental scale. Illumina's spatial transcriptomics technology was described as supporting millions of cells per slide, with a capture area 9 times larger and resolution 4 times greater than preceding alternatives referenced by the company. Bruker's 2025 spatial portfolio included a 1,200-plex protein panel, while its timsUltra AIP technology reported up to 35% more peptide and 20% more protein identifications. These improvements are expanding research capacity across oncology, precision medicine, drug discovery and systems biology.

North America Multiomics Market Drivers

Scaling Precision Medicine and High-Resolution Biological Research

Precision medicine is driving laboratories toward simultaneous measurement of DNA, RNA, proteins and epigenetic signals rather than isolated assays. Illumina's 5-base workflow, released in 2025, combines genomic variant and DNA-methylation detection within 1 workflow, while its spatial platform targets millions of cells per slide. Bruker's timsUltra AIP reports improvements of up to 35% in peptide and 20% in protein identifications. Together, these advances increase information generated per biological sample and support broader adoption across oncology, rare disease research and therapeutic development.

North America Multiomics Market Restraints

Computational Complexity and Data Harmonization Limit Scalable Deployment

Multi-layer studies can combine 2–7 major omics categories, creating substantial requirements for storage, normalization, statistical validation and bioinformatics expertise. Research literature continues to identify simultaneous multi-omics probing and post-hoc integration as technical challenges, particularly for single-cell transcriptomic and proteomic datasets. Meanwhile, emerging spatial-proteomics models have been trained across 175 protein markers, 16 tissue types and 8 imaging platforms, illustrating both the scale of modern datasets and the computational burden associated with cross-platform standardization.

North America Multiomics Market Opportunities

Single-Cell, Spatial Biology and AI Create New Commercial Workflows

Spatial biology provides opportunities to integrate molecular identity with tissue location at increasingly high resolution. Bruker announced a 1,200-plex GeoMx protein panel in 2025, while Illumina reported spatial transcriptomics with a 9-times larger capture area and 4-times greater resolution relative to referenced existing technologies. AI further expands commercialization opportunities: KRONOS, for example, was trained on more than 47 million image patches spanning 175 markers and 16 tissue types, highlighting the emerging intersection between large-scale molecular datasets and machine-learning applications.

Chalanges in North America Multiomics Market

Reproducibility, Interoperability and Specialized Infrastructure Remain Critical

Combining genomic, transcriptomic, proteomic and metabolomic measurements requires harmonization across instruments, sample-preparation protocols and computational pipelines. Modern studies can encompass millions of cells, 1,000-plus protein targets and multiple molecular modalities, magnifying batch effects and validation requirements. Bruker's GeoMx panel expanded from approximately 1,000-plex to 1,200-plex capabilities during 2025 announcements, while Illumina's spatial approach targets millions of cells per slide, demonstrating how rapidly increasing experimental dimensionality places additional pressure on data governance and reproducibility.

Multiomics Market Segmentation

The market is segmented by omics type, application, technology, offering and end user. Within the supplied quantitative segmentation, genomics dominates with approximately 30.6% of 2026 revenue, followed by transcriptomics at approximately 21.7%. Metabolomics records the highest listed CAGR at 16.58%, while the complete omics-type dataset increases from USD 1,524.49 million in 2026 to USD 5,092.84 million by 2034 at 16.28%.

By Omics Type

Genomics is the largest subsegment, increasing from USD 401.48 million in 2025 to USD 466.40 million in 2026 and USD 1,547.07 million by 2034 at 16.17% CAGR. It represents approximately 30.6% of the 2026 omics-type total, supported by sequencing-intensive disease research and integrated molecular profiling.

Metabolomics is the fastest-growing listed subsegment at 16.58% CAGR, reaching USD 571.06 million by 2034 from USD 167.37 million in 2026. Transcriptomics follows at 16.39%, lipidomics at 16.38%, proteomics at 16.25%, genomics at 16.17%, microbiomics at 16.16% and epigenomics at 16.02%.

By Application

Drug discovery and development, precision medicine, biomarker identification, clinical diagnostics, agriculture, nutrigenomics, infectious-disease surveillance and systems biology constitute the application landscape. The supplied tables do not provide application-level revenue or CAGR; therefore, no unsupported market-size values are assigned. Quantified market context remains USD 1,523.50 million in 2026 and USD 5,062.32 million in 2034.

By Technology

Technology segmentation covers next-generation sequencing, mass spectrometry, microarrays, single-cell analysis, real-time PCR and integration platforms. No technology-specific revenue or CAGR is supplied. The broader quantified outlook advances at 16.2% CAGR, while technological capabilities now include millions of cells per spatial slide and protein panels exceeding 1,000 targets.

By Offering

Software and services, instruments and consumables form the offering categories. Revenue and CAGR by offering are not provided in the mandatory dataset and are therefore not estimated. The addressable country-level total expands by USD 3,538.82 million between 2026 and 2034, from USD 1,523.50 million to USD 5,062.32 million.

By End User

Pharmaceutical and biotechnology companies, academic institutions, CROs, hospitals and clinics, and government agencies constitute the end-user base. End-user-specific revenue and CAGR are unavailable in the supplied data. Across the overall forecast, revenue rises more than 3.3-fold between 2026 and 2034, with the stated country-level CAGR at 16.2%.

North America Multiomics Market Counties Outlook

U.S.

The United States generates USD 1,144.23 million in 2026, approximately 75.1% of the North American country total, compared with USD 985.47 million in 2025. Revenue is forecast to reach USD 3,779.81 million by 2034 at 16.11% CAGR, representing an absolute 2026–2034 increase of USD 2,635.58 million. Production-unit and sector-specific splits are not supplied and are not estimated.

Canada

Canada contributes approximately 24.9% in 2026, with revenue increasing from USD 325.69 million in 2025 to USD 379.27 million in 2026. It is forecast to reach USD 1,282.51 million by 2034 at 16.45% CAGR, the faster country growth rate. The 2026–2034 absolute increase is USD 903.24 million; production-volume and sector-split figures are unavailable in the supplied tables.

Top players in North America Multiomics Market

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Bruker Corporation
• QIAGEN N.V.
• Agilent Technologies, Inc.
• 10x Genomics, Inc.
• Bio-Rad Laboratories, Inc.
• Pacific Biosciences of California, Inc.
• Standard BioTools Inc.
• Becton, Dickinson and Company
• Waters Corporation
• SCIEX
• Revvity, Inc.
• Parse Biosciences
• NanoString/Bruker Spatial Biology

Top Two Companies

• Illumina, Inc.

A company-specific percentage share is not provided in the mandatory dataset and is not publicly established by the cited sources, so no unsupported percentage is assigned. Illumina's positioning is supported by its 2025 5-base genomic/epigenomic workflow and the January 2026 commercial release of Connected Multiomics after evaluation by 40 early-access users. Its spatial roadmap additionally targets millions of cells per slide, a 9-times larger capture area and 4-times greater resolution compared with referenced alternatives, reinforcing its position across sequencing, single-cell, spatial and cloud-analysis workflows.

• Bruker Corporation

A verified company-level percentage share is likewise unavailable from the mandatory tables and cited public disclosures; assigning one would require unsupported estimation. Bruker's competitive position is concentrated in spatial biology, mass spectrometry and high-sensitivity proteomics. During 2025, the company announced CosMx same-slide multiomics, a 1,200-plex GeoMx protein panel and timsUltra AIP, whose processor delivered up to 35% more peptide and 20% more protein identifications. These capabilities strengthen its positioning in spatial proteomics, single-cell analysis and high-dimensional tissue research.

Recent Developments in North America Multiomics Market

• 2026:Illumina released Connected Multiomics, a cloud-based platform integrating multiple molecular modalities, following feedback from 40 early-access users.
• 2026:Illumina introduced AI-assisted suggestions in Connected Multiomics version 1.1 to guide exploratory analytical workflows.
• 2025:Illumina launched its 5-base solution for simultaneous genomic-variant and DNA-methylation analysis from a single workflow.
• 2025:Bruker announced CosMx 2.0, same-slide multiomics and a 1,200-plex protein panel for GeoMx DSP at AACR.
• 2025:Bruker introduced timsUltra AIP, reporting up to 35% more peptide and 20% more protein identifications for high-sensitivity proteomics.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 designated as historical years. Mandatory numerical tables supplied for 2 countries and 7 omics categories serve as the primary quantitative source. Country totals of USD 1,311.16 million for 2025, USD 1,523.50 million for 2026 and USD 5,062.32 million for 2034 were retained without alteration. The separate omics-type totals of USD 1,311.16 million, USD 1,524.49 million and USD 5,092.84 million were also retained as supplied despite their difference from country totals. Percentage contributions were calculated directly from the relevant supplied totals, while unsupported application, technology, offering, end-user, production-volume and company-share estimates were deliberately excluded. Public company disclosures were used only for technology and recent-development context.